Literature DB >> 26282426

Optimizing the initial amikacin dosage in adults.

Bryan P White1, Ben Lomaestro1, Manjunath P Pai2.   

Abstract

We report on the pharmacokinetics (PK) and pharmacodynamics (PD) of high-dose (>15 mg/kg of body weight per day) amikacin. A mean (standard deviation [SD]) maximum drug concentration in the serum (Cmax) and 24-h area under the concentration-time curve (AUC24) of 101 (49.4) mg/liter and 600 (387) mg · h/liter, respectively, were observed (n = 73) with 28.0 (8.47) mg/kg/day doses. An initial amikacin dose of 2,500 mg in adults weighing 40 kg to 200 kg with therapeutic drug monitoring to adjust the maintenance dose will optimize its PK and PD.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26282426      PMCID： PMC4604368          DOI： 10.1128/AAC.01032-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.

Authors:  Etienne de Montmollin; Lila Bouadma; Nathalie Gault; Bruno Mourvillier; Eric Mariotte; Sarah Chemam; Laurent Massias; Emmanuelle Papy; Florence Tubach; Michel Wolff; Romain Sonneville
Journal:  Intensive Care Med       Date:  2014-04-01       Impact factor: 17.440

Review 2.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

5.  Optimization of aminoglycoside therapy.

Authors:  G L Drusano; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

6.  Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.

Authors:  A D Kashuba; A N Nafziger; G L Drusano; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.

Authors:  C Burdet; O Pajot; C Couffignal; L Armand-Lefèvre; A Foucrier; C Laouénan; M Wolff; L Massias; F Mentré
Journal:  Eur J Clin Pharmacol       Date:  2014-10-21       Impact factor: 2.953

8.  Study of relationship between volume of distribution and body weight application to amikacin.

Authors:  L Rughoo; L Bourguignon; P Maire; M Ducher
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-06       Impact factor: 2.441

9.  Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Authors:  D P Nicolau; C D Freeman; P P Belliveau; C H Nightingale; J W Ross; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Therapeutic drug monitoring of amikacin in septic patients.

Authors:  Wieslawa Duszynska; Fabio Silvio Taccone; Magdalena Hurkacz; Beata Kowalska-Krochmal; Anna Wiela-Hojeńska; Andrzej Kübler
Journal:  Crit Care       Date:  2013-07-25       Impact factor: 9.097
View more
  10 in total

1.  Reply to Baud and Houzé, "Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?"

Authors:  E Wenzler; M Biagi; X Tan; D A Butler
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 2.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

3.  Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.

Authors:  Ali A Alhadab; Mariam A Ahmed; Richard C Brundage
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.

Authors:  Marie Titecat; Xiaofei Liang; Chul-Jin Lee; Audrey Charlet; Didier Hocquet; Thierry Lambert; Jean-Marie Pagès; René Courcol; Florent Sebbane; Eric J Toone; Pei Zhou; Nadine Lemaitre
Journal:  J Antimicrob Chemother       Date:  2016-06-20       Impact factor: 5.790

5.  Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae.

Authors:  Su Mon Aye; Irene Galani; Heidi Yu; Jiping Wang; Ke Chen; Hasini Wickremasinghe; Ilias Karaiskos; Phillip J Bergen; Jinxin Zhao; Tony Velkov; Helen Giamarellou; Yu-Wei Lin; Brian T Tsuji; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

6.  Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size.

Authors:  Ryan L Crass; Brian E Ross; Brian A Derstine; Matt Lichty; June A Sullivan; Grace L Su; Stewart C Wang; Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 7.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

Review 8.  Amikacin: Uses, Resistance, and Prospects for Inhibition.

Authors:  Maria S Ramirez; Marcelo E Tolmasky
Journal:  Molecules       Date:  2017-12-19       Impact factor: 4.411

9.  Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.

Authors:  Taylor Abbey; Alesia Vialichka; Michele Jurkovic; Mark Biagi; Eric Wenzler
Journal:  Microbiol Spectr       Date:  2022-06-01

10.  High-dose amikacin for achieving serum target levels in critically ill elderly patients.

Authors:  Kourosh Sadeghi; Hadi Hamishehkar; Farhad Najmeddin; Arezoo Ahmadi; Ebrahim Hazrati; Hooshyar Honarmand; Mojtaba Mojtahedzadeh
Journal:  Infect Drug Resist       Date:  2018-02-13       Impact factor: 4.003
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.